The U.S. Food and Drug Administration (FDA) has removed the safety monitoring program and loosened facility restrictions for several CAR-T therapies, including those from Bristol Myers Squibb, Gilead Sciences, Johnson & Johnson, and Novartis. This regulatory shift reflects accumulated clinical experience in managing associated toxicities such as cytokine release syndrome and neurological effects. By eliminating Risk Evaluation and Mitigation Strategies (REMS) requirements, the FDA aims to improve patient accessibility to these personalized cancer treatments. Analysts and the agency agree that facilities and clinicians are now more adept at managing therapy risks, supporting these changes.